Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the Registry of Hypogonadism in Men (RHYME)

International Journal of Clinical Practice

Volumn 70, Issue 10, 2016, Pages 843-852

  Maggi, Mario ^a   Wu, Frederick C W ^b   Jones, Thomas H ^c   Jackson, Graham ^d   Behre, Hermann M ^e   Hackett, Geoffrey ^f   Martin Morales, Antonio ^g   Balercia, Giancarlo ^h   Dobs, Adrian S ⁱ   Arver, Stefan T E ^j   Maggio, Marcello ^k   Cunningham, Glenn R ^l   Isidori, Andrea M ^m   Quinton, Richard ⁿ   Wheaton, Olivia A ^o   Siami, Flora S ^o   Rosen, Raymond C ^o   Meuleman, E ^p   Dohle, G ^p   Wu, F ^p   Porst, H ^p   Jones, H ^p   Lenzi, A ^p   Bouloux, P M ^p   Morales, A M ^p   Stroberg, P ^p   Cruz, N ^p   Yassin, A ^p   Reisman, C ^p   Bassa, L ^p   Pescatori, E ^p   Martinez Salamanca, J I ^p   Romero Otero, J ^p   Jockenhoevel, F ^p   Debruyne, F ^p   more..

^a UNIVERSITY OF FLORENCE   (Italy)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c BARNSLEY HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^d LONDON BRIDGE HOSPITAL   (United Kingdom)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^f Holly Cottage   (United Kingdom)

^g HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^h OSPEDALI RIUNITI   (Italy)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^k UNIVERSITY OF PARMA   (Italy)

^l BAYLOR COLLEGE OF MEDICINE   (United States)

^m SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁿ NEWCASTLE UNIVERSITY   (United Kingdom)

^o NEW ENGLAND RESEARCH INSTITUTES   (United States)

^p NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE; ANDROGEN;

ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; COHORT ANALYSIS; DRUG SAFETY; EUROPEAN; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PREDICTION; PRIORITY JOURNAL; QUESTIONNAIRE; REGISTER; ADVERSE EFFECTS; CHEMICALLY INDUCED; CLINICAL TRIAL; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; ANDROGENS; CARDIOVASCULAR DISEASES; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; REGISTRIES; RISK FACTORS; TESTOSTERONE;

EID: 84992152261     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12876     Document Type: Article

References (34)

1. Kaufman JM. Mortality associated to late-onset hypogonadism: reasons not to treat with testosterone? J Clin Endocrinol Metab. 2014;99:1161–1163.
2. Morgentaler A, Miner MM, Caliber M, et al. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc. 2015;90:224–251.
3. Desroches B, Kohn TP, Welliver C, Pastuszak AW. Testosterone therapy in the new era of Food and Drug Administration oversight. Transl Androl Urol. 2016;5:207–212.
4. Tanna MS, Schwartzbard A, Berger JS, Underberg J, Gianos E, Weintraub HS. Management of hypogonadism in cardiovascular patients: what are the implications of testosterone therapy on cardiovascular morbidity? Urol Clin North Am. 2016;43:247–260.
5. Morgentaler A. Controversies and advances with testosterone therapy: a 40-year perspective. Urology. 2016;89:27–32.
6. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. New Engl J Med. 2010;363:109–122.
7. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS ONE. 2014;9:e85805.
8. Vigen R, O'Donnell CI, Baron AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 310:1829–1836.
9. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use 2015. http://www.fda.gov/Drugs/DrugSafety/ucm436259.htm. Accessed September 7, 2016.
10. Agency of European Medicine. No consistent evidence of an increased risk of heart problems with testosterone medicines 2014 2015-01-17; (EMA/706140). http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/11/news_detail_002218.jsp&mid=WC0b01ac058004d5c1
11. Dohle GR, Arver S, Bettocchi C, et al. Guidelines on male hypogonadism 2015. http://uroweb.org/wp-content/uploads/EAU-Guidelines-Male-Hypogonadism-2015.pdf. Accessed September 7, 2016.
12. Dimopoulou C, Ceausu I, Depypere H, et al. EMAS position statement: testosterone replacement therapy in the aging male. Maturitas. 2016;84:94–99.
13. Goodman N, Guay A, Dandona P, et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of testosterone and cardiovascular risk. Endocr Pract. 2015;21:1066–1073.
14. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374:611–624.
15. Sharma R, Oni OA, Gupta K, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36:2706–2715.
16. Anderson JL, May HT, Lappé DL, et al. Impact of testosterone replacement therapy on myocardial infarction, stroke, and death in men with low testosterone concentrations in an integrated health care system. Am J Cardiol. 2016;117:794–799.
17. Wallis CJ, Lo K, Lee Y, et al. Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. Lancet Diabetes Endocrinol. 2016;4:498–506.
18. Sharma R, Oni OA, Chen G, et al. Association between testosterone replacement therapy and the incidence of deep vein thrombosis and pulmonary embolism: a retrospective cohort study of the Veterans Administration Database. Chest 2016;150: 563–571.
19. Bhattacharya RK, Khera M, Blick G, et al. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS). Clin Interv Aging. 2012;7:321–330.
20. Miner MM, Bhattacharya RK, Blick G, et al. 12-month observation of testosterone replacement effectiveness in a general population of men. Postgrad Med. 2013;125:8–18.
21. Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014;13:1327–1351.
22. Albert SG, Morley JE. Testosterone therapy, association with age, initiation and mode of therapy with cardiovascular events: a systematic review. Clin Endocrinol (Oxf). 2016; 85:436–443.
23. Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract. 2014;68:314–329.
24. Haider A, Gooren LJ, Padungtod P, Saad F. Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. Andrologia. 2009;41:7–13.
25. Haider A, Saad F, Doros G, et al. Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study. Obes Res Clin Pract 2014;8:e339–e349.
26. Rosen RC, Wu FC, Behre HM, et al. Registry of hypogonadism in men (RHYME): design of a multi-national longitudinal, observational registry of exogenous testosterone use in hypogonadal men. Aging Male. 2013;16:1–7.
27. Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18:5–15.
28. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536–2559.
29. Nichols M, Townsend N, Scarborough P, et al. Cardiovascular disease in Europe: epidemiological update. Eur Heart. 2015;36:2696–2705.
30. Hackett G. An update on the role of testosterone replacement therapy in the management of hypogonadism. Ther Adv Urol. 2016;8:147–160.
31. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97:2050–2058.
32. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169:725–733.
33. Ohlsson C, Barrett-Connor E, Bhasin S, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol. 2011;58:1674–1681.
34. Cooper A, Ferro A, Lloyd G, O’Kane P, Waring E, Citrome L. In Memoriam: Dr Graham Jackson, 1947–2016. International Journal of Clinical Practice. 2016;70:638–640.